1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,204 | 0,252 | 29.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Cereno Scientific AB: Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results | 216 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides an update... ► Artikel lesen | |
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 25.09. | Cereno Scientific AB: Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD | 612 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive... ► Artikel lesen | |
| 26.08. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2026 | 587 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 13.08. | Cereno Scientific AB: Cereno Scientific Activates First Clinical Site in Global Phase IIb EPIMODE Trial of CS1 in PAH, Enabling Patient Recruitment | 361 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for rare cardiovascular and pulmonary diseases, today announced that the first... ► Artikel lesen | |
| 08.07. | Cereno Scientific AB: Cereno Scientific Confirms that Members of Management and Chair of Board have Acquired Shares for a Total of Over 1.5 MSEK | 336 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced, that... ► Artikel lesen | |
| 26.06. | Cereno Scientific AB: Cereno Scientific Reports EAP Analyses with CS1 in PAH: Majority of Completing Patients Achieved Stable or Improved Clinical Status over 12 Months | 370 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), a biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today reported further analyses... ► Artikel lesen | |
| 17.06. | Cereno Scientific AB: Cereno Scientific AB (publ) publishes report from the Annual General Meeting 2026 | 528 | GlobeNewswire (Europe) | Today, June 17, 2026, Cereno Scientific AB (publ) held its Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairperson of the Annual General Meeting... ► Artikel lesen | |
| 27.05. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q1 2026 | 1.252 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 11.05. | Cereno Scientific AB: Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension | 538 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced a collaboration... ► Artikel lesen | |
| 04.04. | Cereno Scientific AB: Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH | 978 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides additional... ► Artikel lesen | |
| 31.03. | Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | 516 | PR Newswire | GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 23.03. | Cereno Scientific - Inflection points coming into view | 954 | Edison Investment Research | Cereno Scientific's FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226... ► Artikel lesen | |
| 19.03. | Cereno Scientific - capital markets day highlights (Video) | 904 | Edison Investment Research | In this video, we go behind the scenes at Cereno Scientific's capital markets day, speaking with key stakeholders, including company leadership, industry experts and patients living with pulmonary arterial... ► Artikel lesen | |
| 17.03. | Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | 912 | PR Newswire | GOTHENBURG, Sweden, March 17, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 27.02. | Cereno Scientific AB: Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025) | 1.004 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 20.02. | Cereno Scientific - CMD reaffirms shifting focus to clinical delivery | 662 | Edison Investment Research | Cereno Scientific's recent capital markets day (CMD) centered on CS1's progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by... ► Artikel lesen | |
| 04.02. | Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease | 747 | PR Newswire | GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 04.02. | Cereno Scientific AB: Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease | 700 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 03.02. | Cereno Scientific AB: Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026 | 502 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the... ► Artikel lesen | |
| 14.01. | Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases | 496 | PR Newswire | GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ACTIVE BIOTECH | 0,324 | +0,78 % | Active Biotech AB: First cohort under amended protocol succesfully completes safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis | Lund, Sweden - October 13, 2026 Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first safety cohort of three patients enrolled under the amended protocol has successfully completed... ► Artikel lesen | |
| CANTARGIA | 0,122 | +29,68 % | Cantargia Presents Nomination Committee Ahead of 2027 AGM | LUND, SE / ACCESS Newswire / October 29, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today provided notification... ► Artikel lesen | |
| QIAGEN | 45,050 | 0,00 % | Bye, bye Börse: Delisting: DAX-Aktie Qiagen wird wohl bald verschwinden | © Foto: Andreas Arnold/dpaDer Private-Equity-Riese EQT will Qiagen übernehmen. Experten trauen dem Angebot den Durchbruch zu. Der Diagnostik-Konzern dürfte anschließend von der Börse genommen werden.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 288,62 | +1,10 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | 0,00 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | +0,03 % | Kymera Therapeutics: Brookline Capital hebt Kursziel nach Risikoreduzierung an | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | +2,23 % | What's Going On with MoonLake Immunotherapeutics Stock on Thursday? | ||
| TANGO THERAPEUTICS | 22,510 | +1,31 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | +7,51 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | -1,16 % | H.C. Wainwright bekräftigt Kaufempfehlung für 4D Molecular Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 31,980 | +1,78 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,042 (-16,52 %) liegt der Kurs bei 0,213 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.